Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have previously demonstrated that the gonadotropin-mediated inhibition of apoptosis in ovarian granulosa cells is linked to changes in the expression of several cell death-related genes, including members of the
bcl-2
gene family (
bcl-2
, bax, and bcl-x). Recently, the product of the
p53 tumor suppressor
gene, a protein reported to play a critical role in regulating cell proliferation and death, has been shown to directly modulate the transcriptional activity of the
bcl-2
and bax genes. In addition, the actions of
p53
may be amplified through a cooperative interaction with another tumor suppressor protein, the product of the Wilms' tumor suppressor gene (WT-1). Based on our identification of a potential role for
bcl-2
-related factors in regulating granulosa cell apoptosis and the reported function of
p53
as a regulator of
bcl-2
and bax gene transcription in extragonadal cells, the present studies were conducted to determine whether the
p53
and WT-1 genes are expressed and gonadotropin regulated in the rat ovary and to investigate whether granulosa cell apoptosis is linked to elevated levels of tumor suppressor gene expression. Northern blot analysis of total RNA prepared from immature (27-day-old) rat ovaries revealed the presence of a single
p53
messenger RNA (mRNA) transcript (2.0 kilobases) and multiple WT-1 messages (1.8, 3.5, and 7.5 kilobases). Subcutaneous injection of immature rats with 10 IU equine CG (eCG) reduced the levels of
p53
and WT-1 mRNA to 71 +/- 9% (P < 0.05) and 46 +/- 3% (P < 0.05), respectively, of saline-treated control levels after 2 days. The inhibition of tumor suppressor gene expression by eCG treatment was associated with a marked reduction in the number of apoptotic granulosa cells and atretic follicles. Furthermore, immunohistochemical analysis revealed that
p53 protein
was localized exclusively to nuclei of apoptotic granulosa cells of atretic follicles, and that
p53
immunostaining was reduced to undetectable levels after in vivo treatment with eCG. To further evaluate whether granulosa cell apoptosis is linked to increased expression of tumor suppressor genes, we analyzed levels of
p53
and WT-1 mRNA in antral follicles induced to undergo atresia in vitro by serum-free culture.(ABSTRACT TRUNCATED AT 400 WORDS)
...
PMID:Expression of the p53 and Wilms' tumor suppressor genes in the rat ovary: gonadotropin repression in vivo and immunohistochemical localization of nuclear p53 protein to apoptotic granulosa cells of atretic follicles. 789 50
Activation-induced apoptosis has been proposed as a mechanism for purging the immune repertoire of anti-self specificities, not only in development but also during the generation of somatic mutation in germinal centers. The pathways involved in driving immature and mature T and B cells to programmed cell death are reviewed with respect to two hypotheses, the pre-emptive death model, in which certain signals are obligatory for programmed cell death, and the two signal: death/survival model. Depending on the system, some data support the former pathway, in which certain signals are obligatory for programmed cell death, whereas other data are consistent with the two signal hypothesis. Moreover, recent data suggests that the c-myc protein plays a pivotal role in controlling this process. Finally conflicting roles of protein kinases,
bcl-2
and
p53
are reviewed and contrasted for involvement in activation-induced cell death in T and B lymphocytes.
...
PMID:Activation-induced apoptosis in lymphocytes. 791 17
Multistep lymphomagenesis involves the deregulation of oncogenes and inactivation of tumor suppressor genes resulting in altered rates of proliferation as well as apoptotic cell death in tumor cells. The contribution of
bcl-2
and
p53
to the regulation of cell death during lymphomagenesis is assessed using
bcl-2
-1g,
p53
'knock-out' (
p53
KO), and
p53
KO/
bcl-2
hybrid mice. PCR-SSCP and DNA sequence analysis demonstrated that
p53
somatic mutations are uncommon in lymphomas arising in
bcl-2
-Ig transgenic mice. Reduction in tumor latency was not observed in
p53
KO/
bcl-2
hybrid mice compared to
p53
KO mice. Furthermore, overexpressed
bcl-2
suppressed wild-type p53 associated apoptosis following gamma-radiation. These findings indicate that
bcl-2
and
p53
serve a suppressor and effector function, respectively, of a common cell death pathway. These findings also suggest that
p53
somatic mutations provide no selective advantage during in vivo multistep lymphomagenesis in the context of
bcl-2
gene deregulation.
...
PMID:Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. 793 33
Immunohistochemical characteristics of undifferentiated carcinomas of the ovary were examined using formalin-fixed, paraffin-embedded tissues with an avidin-biotin staining approach. Eight cases were collected from the pathology files of our Institute from a total of 214 recorded malignant ovarian tumors. For immunostaining, antibodies reacting with epithelial membrane antigen (EMA), pankeratin, vimentin, CA 125, CA 19-9, carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), alpha-1-antitrypsin (AT), epidermal growth factor receptor (EGFR), c-erbB-2,
bcl-2
and
p53
proteins were used. All the cases examined were positive for EMA and pankeratin, specific markers for epithelial tumors, negative for the non-epithelial tumor marker, vimentin, and also positive for EGFR. Interestingly, only one case was positive for CA 125, despite it being one of the commonest reported indicators of ovarian cancer. CA 19-9 was positive in 7 cases, CEA in 5, AFP in 2, AT in 6 and c-erbB-2 protein in 4. Two cases were positive for
p53 protein
, and in 1 of these positive staining for
bcl-2
was also observed. These results indicate that the epithelial nature is well preserved in undifferentiated ovarian carcinomas, although consistently positive reactions were not observed within the cases for some antigens. They further clearly show that a negative signal for CA 125 can not be considered to exclude the possibility of a primary ovarian tumor.
...
PMID:Immunohistochemical characterization of undifferentiated carcinomas of the ovary. 796 44
BCL-2 protein plays a pivotal role in overriding programmed cell death (apoptosis), thus favouring a prolonged survival of normal and neoplastic cells. Expression of the
bcl-2
gene has been documented in some human tumours (non-Hodgkin's lymphomas and prostatic adenocarcinomas), but findings in breast carcinomas have not been reported. We have used the monoclonal antibody 124 to investigate BCL-2 expression in 212 breast carcinomas, and to correlate it with the oestrogen (ER), progesterone (PR) and epidermal growth factor receptor (EGFR) status, and with other clinicopathological variables including tumour type, grade, stage, growth fraction (as evaluated by Ki-67 immunostaining), and
p53
accumulation. Of the 212 carcinomas, 173 (81.6%) exhibited BCL-2 immunoreactivity in more than 25% of the neoplastic cells. BCL-2 immunoreactivity was strongly correlated with ER and PR expression (P < 0.00001), with the lobular type (P = 0.012) and with better differentiated neoplasms (P = 0.00003), whereas it was inversely correlated with EGFR (P < 0.00001),
p53
(P = 0.0004) and Ki-67 (P = 0.0002) immunoreactivities. No association was found with tumour stage (T and N categories). We conclude that
bcl-2
expression in breast cancers is related to the oestrogen-dependent transcription pathway.
...
PMID:The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. 798 3
Five cases of intravascular lymphomatosis (IVL) are reported. Diffuse or focal cerebral signs suggestive of vascular disease occurred in four cases, but case 5 presented with symptoms similar to Creutzfeld-Jakob disease. Clinical course ranged from two to eight months and diagnosis was made in all cases by autopsy. Neoplastic lymphoid cells mainly lodged in lumina of small vessels in many organs, but infarction was confined to the CNS. Some extravascular tumor cells were regularly seen. All cases corresponded to high-grade Non-Hodgkin lymphomas of B-cell type and displayed high proliferation indices. Different from findings in primary cerebral and nodal lymphomas, neither
p53
nor
bcl-2
oncoproteins were detectable. Absence of EBV genome and EBV latent membrane protein from IVL was demonstrated for the first time.
...
PMID:Intravascular lymphomatosis of the CNS: clinicopathologic study and search for expression of oncoproteins and Epstein-Barr virus. 798 93
We have studied the ability of c-myc and
bcl-2
oncogenes to modulate
p53
function. Our studies show that coincident expression of human Bcl-2 protein with
p53
prolongs survival of murine erythroleukemia cells. This effect was associated with a loss of the G1 specificity of
p53
-mediated cell cycle arrest. Furthermore, we found that the c-myc and
bcl-2
genes cooperate to inhibit
p53
functions. Coexpression of
bcl-2
and c-myc can totally overcome
p53
-induced apoptosis and cell cycle arrest by altering the subcellular trafficking of
p53
during the cell cycle: the
p53
remains in the cytoplasm of the cotransfected cells during a critical period in G1. This finding suggests a mechanism by which normal hematopoietic progenitors can survive and proliferate despite
p53
expression and by which the inappropriate expression of
bcl-2
and c-myc can cooperate in transformation.
...
PMID:c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. 801 82
A phenotypic and molecular evaluation was made of 15 patients with mature B-cell leukemia/lymphoma showing exclusive spleen and bone marrow involvement. According to French-American-British criteria, these cases could not be classified as classical B-cell chronic lymphocytic leukemia, hairy cell leukemia and its variant forms, splenic lymphoma with villous lymphocytes, or leukemic phase non-Hodgkin's lymphoma (NHL; follicular or intermediate type). The immunophenotype pattern (high surface Ig and CD25 expression, and little or no reactivity with CD5, CD23, and CD11c) and cytomorphologic features of these neoplasms suggested an origin in the marginal zone of the spleen. Molecular analysis did not show any involvement of the dominantly acting oncogenes generally associated with lymphoid malignancies (c-myc,
bcl-2
, bcl-1, Ras), but mutations of the
p53 tumor suppressor
gene involving exons 5, 6, and 8 were found in 6 cases (6 of 15, 40%). In 4 cases, the
p53
alterations consisted of a point mutation leading to amino acid substitution. In the remaining 2 cases, an insertion or deletion resulting in a frame-shift of the protein was observed. In all but 1 of the cases, the wild-type sequence at the mutation site was barely visible, implying the loss of the normal
p53
allele in leukemic cells. All of the cases showed a clinical course compatible with that of low-grade NHL, regardless of the
p53
loss/mutation. Overall, our data suggest the existence of a form of splenic B-cell leukemia/lymphoma of possible marginal zone origin in which
p53
inactivation may play an important pathogenetic role.
...
PMID:Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal zone origin. 801 22
The use of antisense oligonucleotides as a therapeutic tool in modulating gene expression represents a newly established strategy for treating diseases. Such oligomers may be designed to complement a region of a specific gene or messenger RNA. Using this approach, oligonucleotides can serve as a potential block of transcription or translation through sequence-specific hybridization with targeted genetic segments. In the Fourth Meeting of the Italian Society of Experimental Hematology "Discutiamone Insieme", authors reported the use of in vitro synthesized oligonucleotides to inhibit normal and chimeric gene expression of
bcl-2
in normal and neoplastic cell lines, respectively, that carry the t(14;18) translocation. The roles of c-myb and B-myb in the control of the proliferation and differentiation of normal hematopoietic cell lines have been investigated by selective inhibition of the expression of specific transcripts. To get some insight into the correlation between proliferation and differentiation in myeloid cells, some authors studied and reported the differentiation potential of G1-arrested cells obtained by a specific oligodeoxynucleotide complementary to the 5' region of the c-myb mRNA. The use of anti-
P53
antisense oligos in the modulation of the growth of normal and neoplastic bone marrow progenitors was presented and confirmed the pivotal role of this gene in cell cycle control. The role of abl gene expression in normal and chronic myelogenous leukemia (CML) cells is not yet completely understood. Selective inhibition of this proto-oncogene and of the abl-bcr oncogene have been achieved by using of c-abl sequence specific antisense oligonucleotides; this approach sheds new light on the function of this gene in CML.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Meeting report: antisense oligonucleotides. 806 71
Apoptosis, or programmed cell death, is defined by morphologic change resulting in nonpathologic cell loss and is relevant to a wide spectrum of biology. The process is best characterized in the nematode Caenorhabditis elegans where ced genes mediate the death of specific cells during development. Some corresponding genes have been identified in mammalian cells. Expression of the mammalian
bcl-2
gene (homologous to ced-9) suppresses apoptosis in many systems. The ced-3 gene is homologous to a mammalian protease. Increased levels of the
tumor suppressor p53
due to DNA damage may result in either blockage of the cell cycle at G1 or apoptosis. Mutation of
p53
is associated with decreased cell death from radiation and cytotoxic drugs. Initiation of the apoptotic pathway may occur as a consequence of conflicting growth signals. Hierarchical relationships variously between
bcl-2
,
p53
, myc, and other genes indicate a complex pattern of regulation. Stimuli resulting in apoptosis may cause production of free radicals and increased intracellular calcium concentration. The relationship of these changes to the hallmark of apoptosis, internucleosomal fragmentation of DNA, is unclear, and "laddering" of DNA is not always evident. Apoptotic DNA degradation probably occurs sequentially, initially involving breakage into 50 kilobases or larger fragments. The nuclease(s) responsible have not been identified, but deoxyribonuclease I is implicated. The association between nuclease activation and chromatin condensation is complex, and programmed cell death may be subject to cytoplasmic regulation. Available data suggest that clearer understanding of apoptosis will result in better cancer therapy.
...
PMID:Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. 806 87
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>